Baseline characteristics of 185 HCT recipients who underwent autopsy between 1 January 2000 and 31 December 2017
| Characteristic . | No. of patients (%) . |
|---|---|
| Male sex | 115 (62.2) |
| Indication for HCT | |
| AML/MDS | 65 (35.1) |
| Acute lymphoblastic leukemia | 24 (13.0) |
| Chronic myelogenous leukemia | 7 (3.8) |
| Chronic lymphocytic leukemia | 6 (3.2) |
| Hodgkin lymphoma | 3 (1.6) |
| Non-Hodgkin lymphoma | 53 (28.6) |
| Multiple myeloma | 11 (5.9) |
| Other (eg, breast cancer, myelofibrosis) | 16 (8.6) |
| HCT donor type | |
| Autologous | 31 (16.8) |
| Allogeneic | 154 (83.2) |
| HLA-identical related donor | 67 (36.2) |
| HLA-matched unrelated donor | 62 (33.5) |
| HLA-mismatched related donor | 1 (0.5) |
| HLA-mismatched unrelated donor | 17 (9.2) |
| HLA-haploidentical donor | 4 (2.2) |
| Umbilical cord blood | 3 (1.6) |
| HCT allograft source | |
| Mobilized peripheral blood | 165 (89.2) |
| Bone marrow | 17 (9.2) |
| Umbilical cord blood | 3 (1.6) |
| HCT preparative regimen | |
| Myeloablative | 119 (64.3) |
| Nonmyeloablative/reduced-intensity | 66 (35.7) |
| GVHD incidence | 108 (59.7) |
| Characteristic . | No. of patients (%) . |
|---|---|
| Male sex | 115 (62.2) |
| Indication for HCT | |
| AML/MDS | 65 (35.1) |
| Acute lymphoblastic leukemia | 24 (13.0) |
| Chronic myelogenous leukemia | 7 (3.8) |
| Chronic lymphocytic leukemia | 6 (3.2) |
| Hodgkin lymphoma | 3 (1.6) |
| Non-Hodgkin lymphoma | 53 (28.6) |
| Multiple myeloma | 11 (5.9) |
| Other (eg, breast cancer, myelofibrosis) | 16 (8.6) |
| HCT donor type | |
| Autologous | 31 (16.8) |
| Allogeneic | 154 (83.2) |
| HLA-identical related donor | 67 (36.2) |
| HLA-matched unrelated donor | 62 (33.5) |
| HLA-mismatched related donor | 1 (0.5) |
| HLA-mismatched unrelated donor | 17 (9.2) |
| HLA-haploidentical donor | 4 (2.2) |
| Umbilical cord blood | 3 (1.6) |
| HCT allograft source | |
| Mobilized peripheral blood | 165 (89.2) |
| Bone marrow | 17 (9.2) |
| Umbilical cord blood | 3 (1.6) |
| HCT preparative regimen | |
| Myeloablative | 119 (64.3) |
| Nonmyeloablative/reduced-intensity | 66 (35.7) |
| GVHD incidence | 108 (59.7) |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.